Skip to content

Author

B. Claggett

We have 9 of 103 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Abstract 16691: High-Dose versus Standard-Dose Influenza Vaccine in Older Adults with Neurological and Cerebrovascular Disease: A Prespecified Analysis of the DANFLU-2 Trial

Background: Adults with neurological or cerebrovascular (NeCVD) disease have an elevated risk of influenza-related complications. Whether HD-IIV provides greater relative benefit over SD-IIV in this population is uncertain. Objective: To evaluate the relative vaccine effectiveness (rVE) of high-dose inactivate...

M. Yafasov, N. Johansen, D. Modin et al. · 0 citations
Open access Oct 2026

Lung ultrasound in ambulatory adults with HFpEF: Association between pulmonary congestion and one-year outcomes

Early detection of congestion among adults with heart failure and preserved ejection fraction (HFpEF) is critical to optimize therapy prior to overt decompensation, yet traditional tools are insensitive. We sought to examine the association between B-lines on lung ultrasound (LUS) in ambulatory adults with HFpEF...

Elke Platz, K. McDowell, Deepak K. Gupta et al. · 0 citations
Aug 2026

Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults.

BACKGROUND Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-associated respiratory illness, but data fro...

M. Lassen, S. Christensen, M. Yafasov et al. · 1 citation
Open access 2027

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty...

C. Espersen, N. Johansen, D. Modin et al. · 0 citations
#protein folding Open access Oct 2026

RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial.

In adults aged 60 years or older, RSVpreF vaccination reduced hospitalisations for RSV-related respiratory tract disease with no statistical evidence of effect modification by immunosuppression status; however, the study was not powered to exclude subgroup differences.

A. Reimer Jensen, M. H. Højbjerg Lassen, N. Johansen et al. · 0 citations
Open access Aug 2026

The HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 Diabetes.

BACKGROUND Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) face high but modifiable risks of incident heart failure (HF). We aimed to ascertain whether the HFpEF-ABA score, a simple 3-variable tool to facilitate timely diagnosis of HFpEF, is associated with adverse cardiovascular (CV) outcomes in p...

R. Inciardi, J. Ostrominski, B. Claggett et al. · 0 citations
Sep 2026

Atrial Fibrillation in Genotyped Dilated Cardiomyopathy: Epidemiology, Risk Factors, and Outcomes: Insights From the SHaRe Registry.

BACKGROUND Atrial fibrillation (AF) is the most common arrhythmia in dilated cardiomyopathy (DCM) and is associated with adverse outcomes. However, the genetic determinants of AF risk and its prognostic significance across genotyped DCM subtypes remain unknown. METHODS In this observational cohort study, we analyzed...

I. Balakrishnan, A. Heymans, B. Claggett et al. · 0 citations
Open access Aug 2026

Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

A prediction model is developed to estimate the short-term treatment effects of combination medical therapy on systolic blood pressure (SBP), diastolic BP, estimated glomerular filtration rate (eGFR) and serum potassium and individualized estimates of the expected treatment effect are provided.

Nelson Wang, B. Claggett, M. Pfeffer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.